CRBP Corbus Pharmaceuticals Holdings Inc.

6.66
0  0%
Previous Close 6.66
Open 6.67
Price To Book 14.48
Market Cap 430,721,467
Shares 64,672,893
Volume 280,755
Short Ratio
Av. Daily Volume 725,954
Stock charts supplied by TradingView

NewsSee all news

  1. Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

    - Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a

  2. Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

    Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation Stable background use

  3. Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

    - Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST - Norwood, MA , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a

  4. Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

    Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile continues with no serious

  5. Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

    Phase 3 "RESOLVE-1" study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data due summer of 2020.
Anabasum (Resunab)
Cystic Fibrosis
Phase 2 data due 2020.
Anabasum (Resunab)
Systemic lupus erythematosus (SLE)
Phase 3 data due 2021.
Lenabasum (resunab) - DETERMINE
Dermatomyositis
Phase 3 top-line data due summer 2020.
Resunab - RESOLVE-1
Systemic Sclerosis
Phase 1 trial to be initiated in 2020.
CRB-4001
Nonalcoholic steatohepatitis (NASH)

Latest News

  1. Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System

    - Live video webcast on Friday, December 13, 2019 from 1:00 PM – 2:30 PM ET Norwood, MA, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a

  2. Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis

    Company expects to report topline data from study in the summer of 2020Primary endpoint of this study is reduction in pulmonary exacerbationsStudy enrolled participants regardless of CFTR mutation Stable background use

  3. Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London

    - Presentation with live audio webcast on Wednesday, November 20th at 5:20 PM DST - Norwood, MA , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or the "Company"), a

  4. Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting

    Median ACR CRISS score remains 0.95 at 25 months in systemic sclerosis OLE Improvement in CDASI activity score reaches -20.9 points at 23 months in dermatomyositis OLE Favorable safety profile continues with no serious

  5. Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates

    Phase 3 "RESOLVE-1" study of lenabasum for treatment of systemic sclerosis on track for topline results in summer of 2020Systemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan

  6. Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019

    - Company to host conference call and webcast on Thursday, November 7 at 8:30 a.m. ET -                Norwood, MA, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) ("Corbus" or

  7. Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting

    New lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presentedSystemic sclerosis is a rare autoimmune disease affecting ~200,000 people in the U.S., EU and Japan and has